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ABSTRACT
An increasing number of studies have shown an inverse association between a personal
history of cancer (PHC) and dementia/Alzheimer’s disease (AD), both in those using
dementia/AD as the outcome or cancer as the outcome. This is the first study to examine this
potential association in Japanese Americans; and to examine family history of cancer and its
association with incident dementia. Also, the association between these two diseases in the
parents of participants were analyzed.
The Kame Project, conducted from 1992 through 2001 in King County, Washington was
a population-based, prospective cohort study of older Japanese Americans. Conversion to
incident dementia was observed throughout the follow-up period and diagnosed by standard
criteria in a consensus conference.
A PHC did not have a significant association with the development of dementia.
Differences between this study and those conducted previously showing an inverse association
between cancer and dementia or AD included a lower age of the present cohort, race/ethnicity,
focus on all-cause dementia vs. AD and adjustment for the competing risk of death. A family
history of cancer was inversely associated with the development of dementia. There were
statistically significant trends for a dose-response association between the numbers of affected
relatives with cancer and risk for dementia. The findings are most likely explained by an inverse
genetic association between cancer and dementia. Older Japanese Americans (the parents) with a
history of cancer were nearly 2.5 times less likely to have a history of dementia than those
without a cancer history.
v

CHAPTER ONE:
THE ASSOCIATION BETWEEN A PERSONAL HISTORY OF CANCER AND
INCIDENT DEMENTIA IN JAPANESE AMERICANS: THE KAME PROJECT

Introduction
There is a growing body of epidemiologic evidence supporting a protective effect for
cancer survivors in the development of AD.1-3 The three cited, recently conducted meta-analyses
all show approximately a one-third reduced risk for the development of AD.
The evidence for an inverse association among all-cause dementia is less robust. A
nested-case control study in Sweden showed an inverse association among all cancer types and
dementia.4 However, two prospective studies (the Framingham Heart Study and Einstein Aging
Study) reported hazard ratios (HR) below one, but their findings were not statistically
significant.5, 6
The current study is the first to investigate the relationship between cancer and dementia
among Japanese Americans. Our a priori hypothesis was that there would be an inverse
association between a personal history of cancer (PHC) and incident dementia in this population.
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Methods
Study Population
The Kame Project was a prospective cohort study of older Japanese Americans in King
County, Washington from 1992 through 2001. The baseline examination was completed by
1,985 of 3,045 cohort eligible participants (65.2%) who were at least 65 years old (Figure 1.1).
The number of prevalent dementia cases was 150, and 190 participants were lost to follow-up.
The baseline questionnaire, given by an interviewer and completed by either the participant or
their proxy, included a section on personal medical history. This section included information on
various diseases, including cancer and stroke. The methods, prevalence and incidence have been
described in detail previously.7, 8 For the current analyses, only participants who were dementiafree at baseline were included. There were insufficient data on history of cancer for 100
participants and on a history of stroke for 5 participants. Furthermore, 22 participants were
missing data on history of smoking in the sub-analysis. All participants gave written informed
consent, and the study was approved by the University of Washington and University of South
Florida Institutional Review Boards.

Dementia Case Ascertainment
Participant follow-up continued throughout four biennial waves.8 Incident dementia cases
were assessed through repeated screenings of the Cognitive Abilities Screening Instrument
(CASI). When a participant scored 86 of 100 or less on the CASI, they were asked to return with
a proxy informant. At that time, the potential case underwent detailed neuropsychological testing
and received a workup by study clinicians, including laboratory testing and imaging if deemed
necessary. Diagnoses were made by a consensus conference using DSM-IV criteria for
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dementia.9 Each case was also sub-classified as vascular dementia (VaD) or Alzheimer’s disease
(AD) if they met the criteria.10, 11 If they did not meet DSM-IV criteria for dementia, they were
placed back in the non-demented cohort and followed biennially. The current analysis
investigates all-cause dementia as the outcome.

Covariate Ascertainment
The personal history questionnaire asked participants if they had been diagnosed with
cancer other than skin cancer. Previous and current cancers were combined into one composite
cancer variable. All covariates were dichotomized, History of cancer and history of stroke were
coded either yes or no; Education was divided into those with 12 years of education or less and
those with more than 12 years of education. Smoking was dichotomized into ever (currently or
in the past) versus never smoking. The investigation of comorbidities (including histories of
Type II diabetes, coronary heart disease and hypertension, which were not associated with
dementia and excluded from the final models)6, 12-14 and smoking5, 13, 14 is consistent with
previous cancer-dementia studies.

Statistical Analyses
All independent variables analyzed were assessed at baseline. Baseline characteristics
(sex, education, history of smoking, history of stroke and survival status) were compared by
PHC status using the chi-square test. The Student’s t-test was used for baseline age. A p-value
below 0.05 was considered statistically significant for both tests. Age was used as the time scale
in survival analyses. For non-demented participants, the difference between their baseline age
(left-truncation) and their age at loss to follow-up, death or study end (right-censoring) was used
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to determine their contribution to person-years. For demented participants, their dementia age
was calculated as the midpoint between their previous examination and the one at which their
diagnosis occurred.
We used Fine-Gray proportional hazard regression models15 to obtain hazard ratios and
95% confidence intervals for PHC adjusted for age at baseline, sex, education and history of
stroke in model 1, and additionally for history of smoking in model 2. Both models took into
account the competing risk of death (survival status). The models used the left-truncation of
baseline age. The data were analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC).
Written informed consent was obtained from all of the Kame cohort participants included
in the current study. The Kame Project was approved by the University of Washington and
University of South Florida Institutional Review Boards.

Results
Cancer prevalence among the cohort was 9.9% (n = 153), with the remaining 1,387
participants cancer-free at baseline (Table 1.1). There were 172 cases of all-cause incident
dementia in the original Kame cohort,8 but due to missing data for history of cancer and history
of stroke, there were 145 cases (9.4%) in the current analysis. Of these 145 cases, there were 115
cases of AD and 45 cases of VaD. These subtypes are not mutually exclusive, as an individual
can have more than one subtype. The sample consisted of 863 (56.0%) women; 538 (38.8%) of
the participants had more than 12 years of education; 44 participants (3.2%) had had a stroke;
and 749 (48.6%) were ever smokers. The overall average age at baseline was 71.9 years (SD =
5.5) for participants without a history of cancer and 72.8 years (SD = 5.2) for those with a history
of cancer. There were no statistically significant differences between participants with and
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without a history of cancer for any of these variables. There was a statistically significant
difference (P <0.01) for survival status at the end of the study period.
Table 1.2 shows the univariate analysis and final multivariate models (Model 1 and 2).
The univariate hazard ratio for dementia associated with a PHC was 1.07 (95% CI = 0.65-1.76).
Covariates that statistically significantly associated with the development of dementia in the
crude analysis included education (HR = 0.62, 95% CI = 0.42-0.90) and history of stroke (HR =
2.18, 95% CI = 1.09-4.37). In Model 1, the association between PHC and incident dementia was
HR = 1.13 (95% CI = 0.69-1.86). Education (HR = 0.63, 95% CI = 0.42-0.94) and history of
stroke (HR = 2.14, 95% CI = 1.05-4.32) were independently associated with dementia. The
addition of history of smoking to the second model attenuated the potential association with
dementia (HR = 1.06, 95% CI = 0.63-1.79). In this model, education and history of stroke were
no longer statistically significant.
Age-specific risks for dementia are shown in Table 1.3. Participants who were age 70 or
younger at baseline showed a higher point estimate (HR = 3.01) in Model 1 and (HR = 2.02) in
Model 2 than those older than 70 (HR = 0.96) and (HR = 0.94), respectively. However,
differences between age-specific HRs were not statistically significant. We also tested whether
those who survived to the end of the study had a different adjusted hazard ratio from those who
died during the study and did not find significant differences between these groups.

Discussion
The results from this population-based, prospective cohort study did not show that having
had cancer was inversely associated with the development of dementia. Although there was a
tendency for younger participants to show an increased positive association between PHC and
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incident dementia than older participants, neither of the point estimates was statistically
significant and the test for interaction between age group and personal cancer history did not
reveal a significant difference. Furthermore, we did not see a significant difference between the
hazard ratios in those who survived to the end of the study and those who died.
Our findings of no protective effect of personal cancer history on the risk of dementia
need to be interpreted in the context of a substantial number of studies that showed significant
inverse associations between cancer history and dementia or AD risk.5, 6, 13, 14, 16 Because
dementia and death from cancer represent competing risks, apparent protective associations can
occur if individuals who are destined to develop AD die of cancer before manifesting dementia,
while those without cancer are not selected in the same manner. In the present analyses, we used
Fine-Gray proportional hazards regression to address the issue of competing risk of death.
Previous studies have not addressed the competing risk of death. However, Driver et al.5
restricted their sample to individuals who survived to at least 80 and did not see a significant
difference between the HR obtained in that sample and the entire sample that included people
with earlier mortality. We also did not find a significantly different hazard ratio in participants
who were younger versus those who were older at baseline, as might be expected if differential
survival of those with cancer was playing an important role. The point estimate for younger
participants, however, was lower than that for older participants. Other studies also have shown
stronger inverse associations for older participants.4, 16
Two significant differences between our cohort and those of studies showing significant
protective effects are age and race. The mean age in the Kame Project was 71.9 years. The
Framingham Heart Study cohort5 had the same minimum age, but mean age at baseline for those
without cancer was 76 years and with cancer, 77 years. The Bronx Aging Study6 reported a
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mean age at baseline of 78.6 for dementia-free participants and 80.7 years for all-cause dementia,
with study entry also set at 65. Given that participants in the Kame Project were younger, the
higher mean age in the other studies’ may have led to a greater chance of finding an inverse
association between a PHC and incident dementia due to a stronger competing risk of mortality
at higher ages.
The increased point estimate observed in the Kame Project is similar to a previous study
that included African Americans. The Cardiovascular Health Study-Cognition Sub-study of
participants from California, North Carolina, Maryland and Pennsylvania separately analyzed
data on minorities (n = 232), of whom most were African American.6 In this sub-sample, the HR
between cancer and incident VaD and AD was2.57 (95% CI = 1.27-5.23). Most previous studies
have focused on European or European American populations. The results from the present study
of Japanese Americans, when taken into account with the results from African Americans, may
indicate a difference between ethnic groups, particularly in the US.
Another possible reason that we did not observe an inverse association is that we did not
ascertain the presence of skin cancer. The questionnaire asked about the presence of cancer,
excluding skin cancer. Skin cancer is often subdivided into melanoma and non-melanoma skin
cancer (NMSC). NMSC is the most common form of cancer, of which the most commonly
occurring types are basal-cell carcinoma and squamous-cell carcinoma.17 Some of the previous
studies on cancer and incident dementia included or excluded melanoma and/or NMSCs. The
Einstein Aging Study in the Bronx, reported a null association between all cancers and any
dementia (HR = 0.85, 95% CI = 0.56-1.29), while a separate model consisting exclusively of
NMSC cancers yielded a more inverse result that was also not statistically significant (HR =
0.68, 95% CI = 0.35-1.31).6 The Swedish nested-case control study of registry data (N =
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167,080; 19,756 cases) included multiple types of cancers, and treated melanoma and NMSCs
separately.4 Their findings for all cancers (HR = 0.60, 95% CI = 0.52-0.69) fell in between that
of melanoma (HR = 0.44, 95% CI = 0.20-0.97) and NMSCs (HR = 0.77, 95% CI = 0.58-1.04).
We also relied on self-reporting of cancers which is consistent with previous epidemiologic
studies investigating cancer and incident dementia and AD.6, 18, 19
A final possible limitation of our findings was the inclusion of vascular and Alzheimer
cases in the outcome of all-cause dementia. Other studies have reported stronger inverse
associations in Alzheimer’s versus other types of dementia.5, 6, 13 However, given that two-thirds
of cases carried a diagnosis of AD, the inclusion of vascular dementia cases is unlikely to have
completely eliminated an inverse association.
An additional strength of our study was the prospective and uniform identification of
dementia cases. Some previous studies relied on the use of clinical or registry data.4, 16 The
clinical diagnosis of dementia and its subtypes was made by a consensus committee consisting of
a neurologist, geriatrician, internist, neuropsychologist and epidemiologist using standardized
research criteria.20
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Table 1.1. Baseline statistics by cancer status.

N = 1,540
Age at baseline, y
Sex
Male
Female
Education
≤12 years
>12 years
Smoking
Never
Ever
Stroke
No
Yes
Survival status
Survivors
Nonsurvivors

No Cancer (n = 1,387)
% or
No. or mean (SD)
71.9
(5.5)

Cancer (n = 153)
No. or mean
72.8

% or (SD)
(5.2)

612
775

65
88

42.5
57.5

44.1
55.9

P
0.45
0.70

0.92
849
538

61.2
38.8

93
60

60.8
39.2
0.39

688
680

50.3
49.7

81
69

54.0
46.0

1,343
44

96.8
3.2

151
2

98.7
1.3

1,183
204

85.3
14.7

117
36

76.5
23.5

0.20

<0.01

Table 1.2. Results of Fine-Gray Cox proportional hazards models testing unadjusted covariates
with dementia outcome and testing the final model.
N = 1,540

No

Dementia

Univariate

Model 1*

Model 2*

Predictor

dementia (n)

diagnosis (n)

HR (95% CI)

Cancer
No

HR (95% CI)
N = 1,540

HR (95% CI)
N = 1,518

1,260

127

1.00

1.00

1.00

Yes

135

18

1.07 (0.65-1.76)

1.13 (0.69-1.86)

1.06 (0.63-1.79)

Sex
Male

620

57

1.00

1.00

1.00

Female

775

88

1.17 (0.84-1.64)

1.09 (0.77-1.55)

1.10 (0.70-1.73)

Education
≤12 years

833

109

1.00

1.00

1.00

>12 years

562

36

0.62 (0.42-0.90)†

0.63 (0.42-0.94)†

0.67 (0.45-1.01)

Smoking
Never

697

72

1.00

***

1.00

Ever

687

62

1.06 (0.76-1.49)

***

1.12 (0.73-1.73)

1,359

135

1.00

1.00

1.00

Stroke
No

Yes
36
10
2.18 (1.09-4.37)† 2.14 (1.05-4.32)† 2.06 (0.99-4.30)
*Model 1 adjusted for age at baseline, cancer, sex, education and stroke. Model 2 additionally controls for
smoking. †P < 0.05
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Table 1.3. Age-specific risks by baseline age group.
Model 1
Model 2
n
HR (95% CI)
n
HR (95% CI)
655
3.01 (0.80-11.3)
652
2.02 (0.41-10.1)
885
0.96 (0.57-1.64)
866
0.94 (0.54-1.64)
1,518 1.13 (0.69-1.86) 1,518 1.06 (0.63-1.79)
Abbreviations: HR = hazard ratio; CI = confidence interval

Figure 1.1. Participant flow chart.
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CHAPTER TWO:
FAMILY HISTORY OF CANCER IS INVERSELY ASSOCIATED WITH DEMENTIA.
THE KAME PROJECT

Introduction
A personal history of cancer has been shown in some studies to be inversely associated
with incident dementia4-6, 13 as well as Alzheimer’s disease (AD).1-3 Because people with a
personal history of cancer may have a higher risk of dying before manifesting dementia than
those without such a history, inverse associations could be the result of survival bias.
Furthermore, individuals with impending dementia may be less likely to have their cancer
diagnosed promptly.21 If the association is real and is genetically-determined, individuals with
dementia would be less likely to have a family history of cancer in close blood relatives. To
address this issue, we assessed whether a family history of cancer is associated with risk of
incident dementia. To our knowledge, this is the first time this question has been addressed.

Methods
Study Population
Participants were from the Kame Project, a population-based prospective cohort study of
Japanese Americans aged 65 and older residing in King County, Washington between 1992 and
the end of 2001.7, 8 The baseline questionnaire was completed by 1,835 dementia-free
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participants. Participants were asked to complete a family tree diagram of first-degree relatives
before arriving for their first visit at the study site. Each diagram was transposed by the
interviewer into the questionnaire. Data were collected on each family member concerning
whether or not each family member had cancer or experienced memory problems. Of those who
completed the baseline examination, 190 (10.4%) were lost to follow-up and 160 (8.7%) were
excluded from the analysis due to insufficient data (100 for personal history of cancer, 55 for
family history of cancer and 5 for personal history of stroke) (Figure 2.1). The sample size for
the current analysis was 1,481.
Each family member from the questionnaire was uniquely identified. Relatives for whom
data on family history of cancer and dementia were collected included parents, full- and halfsiblings. Children were excluded from the analysis as few had reached high risk ages for cancer
and dementia.
Written informed consent was obtained from all of the Kame cohort participants included
in the current study. The Kame Project was approved by the University of Washington and
University of South Florida Institutional Review Boards.

Dementia Case Ascertainment
Participant follow-up continued throughout four biennial waves. Methods for diagnosis
are detailed elsewhere.7, 8 Briefly, incident cases were assessed through repeated screenings of
the Cognitive Abilities Screening Instrument (CASI). When a participant scored 86 of 100 or
less on the CASI, they were asked to return for a second examination with a proxy informant. At
this time, the potential case underwent detailed neuropsychological testing and was worked up
by a study clinician. A consensus diagnosis was later performed. If the potential case met DSM-
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IV criteria for dementia, they became an incident dementia case.9 Each case was also subclassified Alzheimer’s disease,11 vascular dementia (VaD)10 or other dementias. If a potential
case did not meet DSM-IV criteria for dementia, they were placed back in the non-demented
cohort and followed biennially. This study investigated all-cause dementia as the outcome.

Cancer Case Ascertainment
The personal history questionnaire asked Kame participants if they had been diagnosed
with cancer, with the exception of skin cancer. Previous and prevalent cancers were combined
into one composite cancer variable. Kame Project participants were asked for each first degree
relative, whether or not they had been diagnosed with cancer, leukemia and Hodgkin’s disease.
These three questions were combined into one derived variable for analyses. The family cancer
history variable was classified three different ways: 1) 0 vs. ≥1; 2) 0 vs. 1 vs. ≥2; 3) 0 vs. 1 vs. 2
vs. ≥3.

Covariate Ascertainment
The baseline questionnaire collected data on personal characteristics, including family
size, sex, age (years), education (years), personal history of smoking and personal health history
of stroke. Age at baseline and family size (excluding the participant) were treated as continuous
variables. Education was dichotomized into 12 years or less and more than 12 years. Personal
history of smoking was defined as ever (current or past) or never. A personal history of stroke
was diagnosed by a physician were endorsed as Yes or No.
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Statistical Analyses
Baseline variables were compared by family history of cancer status (yes or no).
Comparisons used the chi-square test for dichotomous variables and the Student’s t-test for
continuous variables. These same covariates were analyzed separately to determine their crude
association with the outcome using Fine-Gray proportional hazard regressions.
All Fine-Gray regression models used age as the time scale.15 For non-demented
participants, the difference between their baseline age (left-truncation) and their age at loss to
follow-up, death or study end (right-censoring) was used to determine their person-years
contribution. For demented participants, their dementia age was calculated as the midpoint
between their previous examination and the one at which their diagnosis occurred. Univariate
and multivariate statistics presented in the tables include the hazard ratio (HR) point estimate and
95% confidence interval. For disease status, the absence of the condition is the reference
category. Men formed the reference group for sex and 12 years or less for education. Covariates
in the final models included family history of cancer, age, sex, education, family size, personal
history of cancer, personal history of smoking and personal history of stroke. A separate final
model was run for each classification of family history of cancer and a P value for trend was
obtained. The data were analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC).

Results
There were 680 participants with no family history of cancer versus 805 participants with
at least one affected FDR (Table 2.1). Women represented a majority of the sample, with a
significant difference (P = 0.03) between the cancer groups in chi-square testing. Participants
with a family history of cancer had a larger family size (mean = 6.67, SD = 2.36) versus those
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without, mean = 6.02, SD = 2.14, P = <0.01); women represented a higher proportion among this
group (P <0.05).
Of participants with a family history of cancer, 7.1% developed dementia versus 10.3%
without a family history of cancer (Table 2.2). Demented and non-demented participants differed
by family history of cancer, education and personal history of stroke (P <0.05) in Model 1. The
first model only dichotomized (two classification levels) family history of cancer.
Table 2.3 shows the results of the final models for risk of all-cause dementia for each
family history of cancer classification. In Model 1, compared to participants without a family
history of cancer, those with at least one affected first degree relative had a reduced likelihood of
developing dementia (HR = 0.63, 95% CI = 0.44-0.91, P = 0.01). Participants with two or more
affected first degree relatives in Model 2 also had a reduced likelihood for dementia (HR = 0.54,
95% CI = 0.31-0.91) (P trend=0.04). Model 3 also showed a significant trend toward reduced
dementia risk with increasing numbers of first-degree relatives with cancer (P trend = 0.04),
particularly among participants with three or more affected first degree relatives (HR = 0.28,
95% CI = 0.09-0.83).
Across all multivariate models, the inverse association with education weakened slightly
as more family history of cancer classifications were added. Family history of dementia, personal
history of coronary heart disease and hypertension, family history of stroke, Type II diabetes,
coronary heart disease and hypertension did not improve the fit of the model. We conducted an
additional analysis using data on Apolipoprotein (APOE), the major known polymorphism
associated with increased risk for Alzheimer’s disease, which was available for a majority of
participants. Adjusting for APOE, there was no change in the model, indicating that it was
neither a confounder nor an effect modifier. Therefore, it was excluded from the final model.
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Discussion
We found that a family history of cancer reduced the risk for incident dementia by about
one-third among Japanese Americans age 65 and over. There was also a significant trend for a
dose-response effect when family history of cancer was analyzed by the number of affected firstdegree relatives. The statistical significance of the trend was strongest when the family history of
cancer variable was dichotomized, weakening slightly as the study’s ability to detect differences
due to lower power was limited. To our knowledge, this is the first evidence that family history
of cancer is inversely associated with an individual’s risk of developing dementia.
Previous studies addressing personal history of cancer and all-cause incident dementia
found inverse associations.4-6, 12, 13, 16, 19, 22 Published meta-analyses based on these studies
showed that personal history of cancer was associated with a marked reduction in risk of
AD.2, 3, 23 In a second paper and in the present analyses, we found that personal history of cancer
was not associated with dementia risk.
No definitive biologic mechanism has been identified in the cancer-dementia association.
Recent research has postulated that cell cycle deregulation may cause cells to exhibit a
preference for either cell proliferation or cell degeneration (apoptosis).24-27 The three genetic
factors garnering the most intensive research interest are the peptidyl-prolyl cis-trans isomerase
nima-interacting 1 (PIN1) tumor suppressor, the tumor protein p53 (p53) enzyme and the
wingless-type murine-mammary tumor virus integration site (Wnt) signaling pathway.24-27 The
up-regulation/over-expression of PIN1, the up-regulation of Wnt and/or the down-regulation of
p53 can cause cell proliferation and lead to cancer, with the reverse being true for cell apoptosis
and AD.25-28 All are associated with τ protein and Aβ plaques. Stressors cause Aβ accumulation,
leading to the activation of p53, followed by τP aggregation and finally neuronal death.27, 28 PIN1
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is involved in τP dephosphorylation and Aβ accumulation.28 The under-expression of PIN1 sets
off two progressions: the overproduction of Aβ-42 causes the accumulation of plaques leading to
the development of AD; and τP aggregation creates NFT leading to the development of AD.29
The inactivation of the Wnt pathway causes Aβ induced neurotoxicity.28 These cell cycle
alterations leading to AD pathogenesis or oncogenesis are indicative of shared genetic pathways
between cancer and dementia/AD.
Both cancer and AD pathogenesis can be modified by epigenetic mechanisms such as
aging, environmental toxins, diet and exercise.30, 31 All of these are known to be risk factors
associated with cancer and dementia. Epigenetic mechanisms affect changes in the cell’s
biology, interfering with the normal cell cycle.27 Additionally, both DNA damage and oxidative
stress are biological factors inherent to aging, and thus factors relevant to the development of
cancer and dementia.25 For example, oxidative stress from the aging process causes a downregulation of PIN1 leading to the buildup of AD pathology.29
It is of interest that family history of cancer and not personal history of cancer was
associated inversely with dementia risk in this study. Associations of personal history of cancer
with genes known to regulate both oncogenesis and apoptosis may be weak in comparison with
specific oncogenes with a more direct connection with the cancer but without an effect on
apoptosis. On the other hand, specific genes know to regulate both oncogenesis and apoptosis,
such as PIN1, p53 and GSK-3, may have inverse effects in AD and cancer. Polymorphisms for
each of these genes have been shown to be related to both cancer and AD.
Family history of a condition can be a protective or a risk factor for a disease, and has
important public health significance.32 It is possible that our results reflect a genetic biomarker or
biologic mechanism that confers protection against dementia for people from a cancer-prone
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family. The up- or down-regulation of PIN1, p53 and Wnt cause an individual’s cells to begin
oncogenesis (cancer) or apoptosis (AD). All three play a role in the accumulation of betaamyloid, the aggregation of tau protein and neuronal death.27, 28 Both disease pathologies are
modifiable by epigenetic mechanisms, including those integral to the aging process.29, 33, 34
The current study has important limitations. The derived cancer variable for FDRs
included all forms of cancer while the personal cancer history excluded skin cancers. One
previous study found a statistically significant inverse association between melanoma and
incident dementia (HR = 0.44, 95% CI = 0.20-0.97)4 while previous studies of non-melanoma
skin cancers and incident dementia found insignificant results.4, 6 However, the incidence of skin
cancer among Japanese and Japanese Americans is lower than that of Americans.35 This study
relied on the self-report of cancer, but previous epidemiologic studies investigating cancer and
incident dementia and AD also did.6, 18, 19 We adjusted for family size to account for the tendency
of larger families to have more members who develop cancer, but did not adjust for age of the
relatives at baseline or age of death of the parents, both of which could be related to incidence of
cancer and AD.
The greatest contribution of this research is that our study marks the first time that family
history of cancer has been investigated in relation to incident dementia. Family history of disease
is indicative of shared genetic, environmental or behavioral risk factors, and has important
implications for public health research. Family history can be considered as a surrogate for a
potential biomarker or set of biomarkers.
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Table 2.1. Baseline comparison between family history of cancer groups, the Kame project.

Baseline Statistics (N = 1,485)
Age at Baseline in years (mean [SD])
Sex (% female)
Percent with >12 years of education
Family Size (mean [SD])*
Percent of ever smokers
Percent with history of cancer
Percent with history of stroke
Percent of survivors
*Family size excludes the participant

No Family
History of
Cancer
(n = 680)
71.98 ± 5.25
52.5
42.0
6.02 ± 2.14
49.9
9.1
3.2
16.5

Family
History of
Cancer
(n = 805)
71.47 ± 4.87
58.1
37.7
6.67 ± 2.36
48.9
10.6
2.5
13.7

P-Value
0.06
0.03
0.09
<0.01
0.70
0.35
0.38
0.13

Table 2.2. Univariate & multivariate hazard ratios (HR) and 95% confidence intervals for
covariates in Model 1.
N = 1,485

n

Family history of cancer
0
680
≥1
805
Sex
Male
660
Female
825
Education
≤12 years
897
>12 years
588
Family size
1,485
Personal history of smoking
Never
746
Ever
728
Personal history of cancer
No
1,338
Yes
147
Personal history of stroke
No
1,443
Yes
42

Dementia (%*)

Univariate
N = 1,485

Multivariate
N = 1,470

71 (10.4)
57 (7.1)

1 (referent)
0.68 (0.48-0.97)

1 (referent)
0.63 (0.44-0.91)

53 (8.0)
75 (9.1)

1 (referent)
1.11 (0.78-1.58)

1 (referent)
1.11 (0.71-1.75)

95 (10.6)
33 (5.6)
128 (8.6)

1 (referent)
0.60 (0.40-0.89)
1.15 (1.07-1.23)

1 (referent)
0.68 (0.44-1.04)
1.17 (1.09-1.25)

65 (8.7)
59 (8.1)

1 (referent)
1.11 (0.78-1.58)

1 (referent)
1.20 (0.78-1.85)

111 (8.3)
17 (11.6)

1 (referent)
1.14 (0.69-1.90)

1 (referent)
1.13 (0.67-1.89)

120 (8.3)
8 (19.1)

1 (referent)
2.28 (1.08-4.83)

1 (referent)
2.45 (1.12-5.36)

* Row percentages
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Table 2.3. Hazard ratios and 95% confidence intervals for family history of cancer using 3
different classifications.
Model 1* (N = 1,470)
Number
0
≥1

P = 0.01
1 (referent)
0.63 (0.44-0.91)

Model 2* (N = 1,470)
Number
0
1
≥2

Ptrend = 0.04
1 (referent)
0.69 (0.46-1.04)
0.54 (0.31-0.91)

Model 3* (N = 1,470)

Number
Ptrend = 0.04
0
1 (referent)
1
0.69 (0.46-1.04)
2
0.64 (0.36-1.13)
≥3
0.28 (0.09-0.83)
*Adjusted for age, death, sex, education, family size, personal cancer history, personal smoking
history and personal stroke history

Figure 2.1. Participant flow chart.
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CHAPTER THREE:
ASSOCIATION IN PARENTS BETWEEN TWO DEADLY DISEASES: CANCER AND
DEMENTIA. THE KAME PROJECT

Introduction
Both cancer and dementia are leading killers of the elderly. A growing number of
epidemiologic studies demonstrate an inverse association between these two conditions. Cancer,
a disease of cell proliferation, and dementia, a disease of cell degeneration, appear to share
common biological mechanisms.
The earliest reported results exploring the relationship between cancer and incident
dementia/AD was carried out in Japan.22 This prospective study of 2,222 Hiroshima and
Nagasaki atomic bomb survivors, a methodologically standardized sister study to the Kame
Project, for which data are analyzed here, sought to determine risk factors for dementia and its
subtypes. The investigators reported an unadjusted odds ratio (OR) for AD only (OR = 0.3, 95%
CI = 0.05-0.98), presenting cancer as a protective factor for AD. However, they did not control
for any of the other variables they reported on (e.g., sex and age).
There have been several other studies investigating cancer and incident dementia and/or
AD. One prospective cohort study drawing on data from the Washington University Alzheimer’s
Disease Research Center and another in the Bronx, New York both reported an inverse
association between cancer history and incident dementia in their full models, but neither
achieved statistical significance.6, 19 A Swedish nested case-control study reported similar
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results.4 There have been a similar number of studies examining the association between
dementia/AD history and incident cancer. However, in comparison with the incident dementia
studies, these achieved statistical significance. A nested-case control study within the
Framingham Heart Study matched on sex and age reported an inverse relationship, excluding
non-melanoma skin cancers.5 A Taiwanese retrospective cohort study reported a similar inverse
association for all cancers.36
In the Kame Project, another population of Japanese, living in King County, WA was
examined with the hypothesis that an inverse association exists between histories of cancer and
dementia in the parents of participants. The associations between a personal history of cancer in
the participant with incident dementia, and that between a family history of cancer in relation to
incident dementia, are presented elsewhere.

Methods
Study Design
The Kame Project was a prospective cohort study of Japanese Americans over age 65 in
King County, Washington from 1992 through 2001. Eighteen-hundred and thirty-five dementiafree participants, or probands, completed the baseline questionnaire. Before coming to the study
site, participants were asked to fill out a family tree of first-degree relatives. This was transposed
by the interviewer into the questionnaire, where each family member was indicated separately.
Cases of dementia discovered at the prevalence phase of the study were excluded from this
analysis.7 Data were gathered for each family member from the non-demented participant on
whether or not the family member experienced memory problems or had cancer. Further
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information on the Kame Project’s prevalence and incidence phases have been published in
detail elsewhere.7, 8

Study Population
This is a cross-sectional analysis examining the parents of Kame participants who were
reported to have cancer and dementia histories. Parents with missing information on cancer
status and/or dementia status (n = 155) and age at death (n = 436) were excluded from analyses.
Further excluded were those who did not reach the age of 65 (n = 747), which is when late-onset
AD/dementia begins. The final sample size included 2,332 parents.

Cancer Case Ascertainment
The family history question on cancer subdivided the disease into three categories:
cancer, leukemia and Hodgkin’s disease. These three questions were combined into one derived
cancer variable for analysis. Previous cancer-dementia studies also relied on cancer selfreport.6, 18, 19

Dementia Case Ascertainment
Kame participants who indicated that a parent had a memory problem were asked to
complete a separate memory grid. Specific questions were asked in order for the investigators to
try to derive DSM criteria from their responses. We used four of these questions to determine if
each parent was likely to have developed dementia: 1) whether the memory problem lasted for 6
months or longer; 2) if the symptoms began gradually or suddenly; 3) how it progressed (give
major response categories here); and 4) whether the symptoms interfered with work or social
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functions. Three raters (ALS, ARB, JAM) independently assessed patterns of the four questions
to determine if each parent had dementia. Agreement to divergent coding decisions were
adjudicated by the three raters.
All Kame cohort participants from whom the current study’s sample is drawn gave
written informed consent. The Kame Project was approved by the University of Washington and
University of South Florida Institutional Review Boards.

Statistical Analyses
Sex and cancer status were compared between those parents judged to have had dementia
and those judged not to have had dementia. using the chi-square test. Student’s t-test was used to
assess the difference in age at death between these groups. A p-value below 0.05 was considered
statistically significant for both tests. Logistic regression analyses were performed to assess
crude associations of cancer, sex and age at death with dementia status. A multivariate logistic
model with dementia status in the parent as the dependent variable examined cancer status, with
sex and age at death as covariates in the model. Data were analyzed using SAS 9.4 (SAS
Institute Inc., Cary, NC).

Results
There were 1,213 (52.0%) mothers and 1,119 (48.0%) fathers in the study (N = 2,332)
(Table 3.1). Fathers were more likely to be reported to have had a history of cancer, 53.4%
versus 46.6% for mothers (P = 0.0001). The mean age at death was 82.5 (84.3 for mothers and
80.6 for fathers). The mean age at death was higher for those who did not have a reported history
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of cancer (83.2 versus 79.8) (P = 0.02). The cancer prevalence for the entire sample was 459
(19.7%) and the dementia prevalence was 251 (10.8%).
Table 3.2 shows the univariate and multivariate statistics for the association between
history of cancer and history of dementia. When the variables were examined one at a time, we
found a highly statistically significant inverse association between cancer in the parents and
dementia in the parents. This association became somewhat weaker, but remained highly
statistically significant (OR = 0.41, 95% CI = 0.25-0.66) when the model was adjusted for sex
and age at death of the parents.

Discussion
Our results confirmed our a priori hypothesis that there is an inverse association between
cancer status and dementia status. Our findings are consistent with the preexisting literature on
dementia and cancer. Notably, the crude OR of 0.32 is almost identical to the 0.3 reported by
Yamada et al.22 The main difference between that study and this one is that our confidence
interval is much narrower. More importantly, the multivariate results revealed that participants
with a history of cancer were 2.44 times less likely to have a history of dementia. The results
were consistent when stratified by sex, although the association was stronger among men than
women (P value significant, data not shown).
The biological mechanism(s) for the cancer-dementia association have not been
definitively identified. There appears to be changes in the cell cycle that cause cells to show a
preference for either cell proliferation or cell death.24-27 The three genetic factors garnering the
most intensive research interest are the PIN1 tumor suppressor, the tumor protein p53 enzyme
and genes in the Wnt signaling pathway.24-27 Changes in the up- or down-regulation of PIN1, p53
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and/or Wnt lead to differing consequences, including cell proliferation (cancer) or cell apoptosis
(AD).25-28 These potential modifiers are associated with phosphorylated tau protein and Aβ
plaques. Accumulation of Aβ and phophorylated tau aggregation eventually lead to neuronal
death.27, 28 Both cancer and AD pathogenesis can be modified by epigenetic mechanisms such as
aging, environmental toxins, diet and exercise.30, 31 All of these are known to be risk factors
associated with cancer and dementia.
The strengths of our study include a large sample size, reporting of family history of
cancer and dementia by initially non-demented participants and a representative population of
Japanese Americans living in King County, WA.7, 8 In our methodologically-standardized sister
study in Japan,22 no adjustments were made for potential confounders. In our study, age at death
and sex were adjusted in the multivariate models. The use of a memory grid in the Kame study
was an additional strength, since it allowed us to get closer to a definition of dementia by DSM
criteria. This study also had a more balanced proportion of parental sex than the previous study.
However, the study has several limitations. Because there was a statistically significant
difference between the age at which those with a history of cancer died (those with a parental
history of cancer died younger), it is possible that there is differential survival based on age at
death. This has been previously suggested in the literature.13, 37 Also, parents who became
afflicted with cancer in previous decades would have had more limited treatment options. If this
bias were present, we would expect that the inverse association we observed may be overestimated. However, there only appears to have been a small effect from such potential survival
bias, as we controlled for age at death. Therefore, survival bias likely was not present to a great
extent. Reporting bias is a limitation arising from the potential difficulty of Kame probands to
accurately recall their parents’ medical history. One possibility is that probands may be more
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concerned with their parents dying from cancer, such that they under-recalled the presence of
memory complaints. This would weaken the observed association if this were the case. A further
limitation is the absence of a temporal sequence, arising from the inability to differentiate which
disease occurred first in this cross-sectional analysis.
An additional explanation for our findings could be the presence of lead time bias. All
participants in the Kame cohort were at least 65 years of age at baseline, and an incipient Kame
dementia patient may have early signs of memory loss that are not diagnosable but still have an
impact on their reporting of their family’s medical history. We performed a stratified analysis of
Kame probands to investigate this possibility. The probands were stratified by incident dementia
status. No differences were observed between these groups (data not shown).
This study’s results lend some of the strongest evidence for an inverse association
between cancer and dementia. Epidemiologic studies in the United States, Sweden, Taiwan and
Japan show consistent findings for this association. Our study, being focused on older Japanese
Americans, suggests that the association holds for other ethnic groups in the United States. All
studies to date have utilized data from pre-existing studies, which were not designed to assess the
association between family history of cancer and dementia. Future longitudinal studies should
specifically address the competing risks of these two diseases, and how their consequences affect
the elderly. Environmental and lifestyle changes that currently increase risk for negative health
outcomes through gene-environment interactions will need to be implemented on a community
public health level, as well as with each individual in order to help prevent these increasingly
prevalent and interrelated diseases.
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Table 3.1. Baseline statistics of the Kame project parents.
No History
History
Kame Parents
of Cancer
of Cancer
BASELINE STATISTICS
(n = 1,873)
(n = 459)
N = 2,332
n (%*)
n (%*)
n (%*)
Sex
Male
1,119 (48.0) 874 (46.7)
245 (53.4)
Female
1,213 (52.0) 999 (53.3)
214 (46.6)
Age at death†
82.5 ± 9.2
83.2 ± 9.2
79.8 ± 8.5
* Column percentages
† The statistics for age: mean ± standard deviation

P-Value
0.0001

0.02

Table 3.2. Univariate & multivariate odds ratios (OR) and 95% confidence intervals for
covariates in the model.

Kame Parents
N = 2,332
Cancer
No
Yes
Sex
Male
Female
Age at death

n (%*)

Dementia (%*)

Univariate
Statistics
OR (95% CI)

1,873
459

231 (12.3)
20 (4.4)

1 (referent)
0.32 (0.20-0.52)

1 (referent)
0.41 (0.25-0.66)

1,119
1,213

66 (5.9)
185 (15.3)

1 (referent)
2.87 (2.14-3.85)

1 (referent)
2.34 (1.73-3.16)

1.07 (1.05-1.09)

1.05 (1.04-1.07)

* Row percentages
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Multivariate
Model
OR (95% CI)
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